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The ubiquitin–proteasome system is known to be utilized by coxsackievirus to facilitate its prop-
agation within the host cells. The present study explores the role of tripeptidyl peptidase II
(TPPII), a serine peptidase contributing to protein turnover by acting downstream of the protea-
some, in regulating coxsackievirus infection. Inhibition of TPPII does not affect virus replication
in cells with functional proteasome. However, when the proteasome is impaired, TPPII appears to
serve as an alternative to maintain low levels of virus infection. Our results suggest an important
function of TPPII in the maintenance of viral growth and may have implications for anti-viral
therapy.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Coxsackievirus type B3 (CVB3) is a widespread, common
etiologic agent causing myocarditis and pancreatitis [1,2]. We
have previously demonstrated a critical role of the ubiquitin–
proteasome system (UPS) in the control of CVB3 replication
within the host cells [3–6]. The UPS is the major intracellular
protein degradative pathway which contributes signiﬁcantly to
the regulation of many essential cellular functions by removing
misfolded and damaged proteins as well as recycling short-lived
regulatory proteins [7,8]. We have provided evidence that CVB3
utilizes the function of the host UPS to enhance their efﬁciency
of replication in the host cells. We showed that inhibition of
the proteasome function by chemical inhibitors signiﬁcantly
reduces CVB3 infectivity in vitro [3,5,6], and results in attenu-
ated myocardial damage in vivo [4].
Proteasome-independent proteolysis has emerging as an alter-
native pathway to the proteasome-mediated protein turnover
[9,10]. Tripeptidyl peptidase II (TPPII) is a giant intracellular serinechemical Societies. Published by E
ripeptidyl peptidase II; UPS,
modiﬁed Eagle’s medium;
, phosphate buffered saline;
rin
Center, University of British
ver, BC, Canada V6Z 1Y6. Fax:peptidase which exhibits both exo- and endo-proteolytic activities
[9,11–13]. It is believed that TPPII acts downstream of the protea-
some to cleave proteasome-generated peptides into tripeptides
that can then be further degraded into free amino acids by amino-
peptidases [9,11–13]. In addition to its role related to general pro-
tein turnover responsible for the maintenance of numerous
fundamental cellular functions, TPPII plays an essential role in
MHC class I antigen processing via further digest proteasomal
products into smaller peptides more suitable for antigen presenta-
tion [14,15]. Adaptive proteolytic responses to impaired protea-
some function have been reported to play a compensatory role in
the regulation of protein degradation. TPPII appears to make an
essential contribution to such proteolytic activities that substitute
for those of the proteasome in proteasome-inhibited cells
[10,16,17]. In the cells with the loss of the proteasome function,
TPPII has been shown to exhibit enhanced activity to complement
proteasomal activities.
The objective of this study is to explore the role of TPPII in the
control of CVB3 infection in the presence or absence of proteasome
inhibition. We demonstrate that inhibition of TPPII does not affect
CVB3 replication in cells with normal functional proteasome. How-
ever, after the loss of the proteasome activity, TPPII activities ap-
pear to serve as an alternative proteolytic pathway to maintain
minimum CVB3 infection as inhibition of TPPII further reduces
CVB3 replication in a synergistic fashion in combination with a
proteasome inhibitor. Our results suggest an important function
of TPPII in the regulation of virus infectivity.lsevier B.V. All rights reserved.
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Fig. 1. Inhibition of TPPII activities does not affect CVB3 replication. HeLa cells were
pre-incubated with various concentrations of protease inhibitors as indicated for
30 min and then infected with CVB3 for 7 h. (A) Cell lysates were collected and
Western blot analysis for the expression levels of viral capsid protein VP1 and
b-actin (loading control) was performed. The results are representative of three
independent experiments. (B) Supernatants of infected cells were harvested for
viral plaque assay. The results are presented as mean ± S.D. (n = 3). #P < 0.001 for
comparison to CVB3-infected, but non-inhibitor treated cells (column 1).
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2.1. Cell culture and reagents
HeLa cells purchased from the American Type Culture Collec-
tion (Rockville, MD) were grown and maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum and 100 lg/ml penicillin/streptomycin (Invitrogen
Life Technologies) at 37 C in a 5% CO2 humidiﬁed incubator.
The mouse monoclonal anti-VP1 antibody was obtained from
DakoCytomation. The monoclonal anti-b-actin antibody was from
Sigma, and the horseradish peroxidase-conjugated secondary anti-
bodies were purchased from Santa Cruz Biotechnology. The protea-
some inhibitors (MG132 and lactacystin), and the TPPII inhibitor
(H-Ala-Ala-Phe-chloromethylketone, H-AAF-CMK) were obtained
from Calbiochem.
2.2. CVB3 infection and inhibitor treatment
HeLa cells were pre-incubated with increasing concentrations
of various inhibitors as speciﬁed in the ﬁgure legends for 30 min.
Cells were then infected with CVB3 (Kandolf strain, from
Dr. Reinhard Kandolf [18], University of Tubingen, Germany) at a
multiplicity of infection of 10 or mock infected with phosphate
buffered saline (PBS) for 1 h. The infected cells were then washed
with PBS and replaced with new DMEM containing fresh inhibitors.
2.3. Western blot analysis
Equal amounts of protein were subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis and then transferred
to nitrocellulose membranes as previously described [19]. The
membrane was blocked with 5% non-fat dry milk solution contain-
ing 0.1% Tween 20 for 1 h. The blots were then probed for 1 h with
primary antibody followed by incubation for 1 h with secondary
antibodies conjugated to horseradish peroxidase-conjugated sec-
ondary antibody. The immunoreactive protein bands were visual-
ized by enhanced chemiluminescence (GE Healthcare).
2.4. Viral plaque assay
The viral titer in the supernatant was evaluated by an agar over-
lay plaque assay as previously described [6]. In brief, supernatant
was serially diluted and overlaid on a monolayer of HeLa cells.
After 1 h incubation, medium was removed and complete DMEM
containing 0.75% agar was added. Three days later, cells were ﬁxed
with Carnoy’s ﬁxative (25% acetic acid, 75% ethanol) and then
stained with 1% crystal violet. The plaques were counted and the
viral titer was calculated as plaque forming unit per milliliter.
2.5. Peptidase assay
The cell lysates were prepared and collected in a lysis buffer
(50 mM pyrophosphate, 50 mM NaF, 50 mM NaCl, 5 mM EDTA,
5 mM EGTA, 100 lM Na3VO4, 10 mM HEPES (pH 7.4), and 0.1%
Triton X-100) containing no protease inhibitors as previously
described [19]. The chymotrypsin-like activity of 20S proteasome
and the TPPII activity were determined using synthetic ﬂuorogenic
substrates, Suc-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin
(Calbiochem) and H-Ala-Ala-Phe-7-amino-4-methylcoumarin
(H-AAF-AMC, Sigma), respectively. Brieﬂy, 50 lg of cellular ex-
tracts was incubated with 75 lM of ﬂuorogenic peptide substrate,
in an assay buffer (20 mM Tris–HCl [pH 8.0], 1 mM ATP, and 2 mM
MgCl2) at 30 C for 1 h. The ﬂuorescence of the released AMC in the
supernatant was measured at a 465 nm emission wavelength using
a Tecan ﬂuorometer (Männedorf, Switzerland).3. Results and discussion
3.1. Inhibition of TPPII activities does not affect CVB3 replication
To determine the role of the TPPII in the regulation of CVB3
infection, we ﬁrst examined the effect of TPPII inhibition on
CVB3 protein expression and progeny virus titers. HeLa cells were
pre-incubated with increasing concentrations of TPPII inhibitor
(H-AAF-CMK) for 30 min, followed by CVB3 infection for 7 h. Pro-
teasome inhibitors, MG132 and lactacystin, were used to show
the effects of proteasome inhibition on CVB3 replication. The
Western blot results in Fig. 1A and plaque assay data in Fig. 1B
showed that treatment with TPPII inhibitor did not result in any
changes of viral protein VP1 expressions and virus titers, respec-
tively. However, proteasome inhibitor MG132 and lactacystin
dramatically reduced viral protein expression and viral growth
rate, in consistent with our previously reports [5,6]. Our results
suggest that the activity of TPPII is not required for the mainte-
nance of viral growth in the host cells which possess normal
proteasome function.
3.2. Synergetic effect of treatment with TPPII and proteasome
inhibitors on CVB3 replication
It has been reported that TPPII can complement proteasomal
activity when proteasome function is damaged [16,17]. We next
determined the role of TPPII in regulating viral infection in cells
with impaired proteasome function. Speciﬁcally, we examined
whether TPPII inhibition can further reduce proteasome inhibi-
tion-mediated suppression of CVB3 replication. HeLa cells were
incubated with increasing doses of TPPII inhibitor in the presence
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Fig. 3. TPPII activities after CVB3 infection. HeLa cells were mock-infected with PBS
or infected with CVB3 for 2, 4, and 6 h in the presence or absence of 5 lM MG132.
Cell lysates were harvested and subjected to TPPII activity assay with a ﬂuorogenic
peptide substrate (H-AAF-AMC) as described in Section 2. The results are displayed
as mean ± standard deviation (S.D.) (n = 3) and the statistical signiﬁcance was
determined using the unpaired Student’s t-test. No statistical differences between
two groups at all three time courses were observed.
J. Zhang et al. / FEBS Letters 585 (2011) 261–265 263of 5 lM MG132. As shown in Fig. 2, treatment with MG132 led to
decreased viral protein VP1 expression and virus titers. Addition of
TPPII inhibitor synergically reduced viral infectivity in a dose-
dependent manner, suggesting that TPPII activity may compensate
for the loss of proteasome function to maintain low levels of CVB3
propagation in the cells.
3.3. TPPII activities after CVB3 infection and treatment of proteasome
and TPPII inhibitors
We further examined the TPPII activity during the course of vir-
al infection. Fig. 3 showed that TPPII activity was not changed at 2,
4, and 6 h post-infection either in the presence or absence of pro-
teasome inhibitor MG132 (5 lM). We have previously demon-
strated that proteasome activities are also unaltered throughout
the time courses of CVB3 infection [5,20]. Together, these results
suggest that CVB3 infection does not appear to affect the activities
of the proteasome and its downstream executor TPPII.
To validate the impact of proteasome inhibitor MG132 and
TPPII inhibitor on chymotrypsin-like activities of the 20S protea-
some and the TPPII activities, we performed proteolytic assays
using two different synthetic ﬂuorogenic peptide substrates. We
found that the different doses of MG132 used in this study (i.e.
2.5, 5, 10, and 20 lM) dramatically decreased the chymotrypsin-
like activity in a concentration-dependent manner as anticipated
(Fig. 4A). However, treatment with different concentrations of
TPPII inhibitor appeared to have no inhibitory effect on proteasome
activities (Fig. 4A), but led to dose-dependent decreases of the
TPPII activities (Fig. 4B). Interestingly, we found that higher doses
of MG132 (i.e. 10 and 20 lM) can also inhibit TPPII activity,β-actin
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Fig. 2. Synergetic effect of treatment with TPPII and proteasome inhibitors on CVB3
replication. HeLa cells were treated with MG132 (5 lM) alone or in combination
with increasing doses of TPPII inhibitor as detailed in the ﬁgure. (A) The protein
expression of VP1 and b-actin (loading control) was determined by Western blot
analysis. The levels of VP1 were quantitated by densitometric analysis using NIH
ImageJ V1.43, normalized to those of b-actin, and presented as fold changes
compared with non-treated cells (which was arbitrarily set a value of 1.0). The data
are representative of three independent experiments. (B) Supernatant was collected
from CVB3 infected cells and virus titers were determined by plaque assays. The
results are presented as mean ± S.D. (n = 3). &P < 0.005 for comparison to MG132
treatment alone.suggesting that the inhibitory effect of MG132 on viral replication
at these doses is a consequence of inhibition of both the protea-
some and the TPPII activities. Finally, we demonstrated that a com-
bination of 5 lM MG132 (a dose with no signiﬁcant inhibition of
the TPPII activity, Fig. 4B), with increasing concentrations of TPPII
inhibitor signiﬁcantly decreased the TPPII activity (Fig. 4C), but
had no inﬂuences on chymotrypsin-like activities (Fig. 4D). Collec-
tively, our results suggest that functional TPPII plays a compensa-
tory role in the regulation of CVB3 infectivity when the proteasome
function is lost.
4. Discussion
Targeting the proteasome has been suggested to be a promising
therapeutic option against infections of many viruses, including
coxsackieviruses [5,6], coronaviruses [21], retroviruses [22],
cytomegaloviruses [23], and inﬂuenza viruses [24]. We have dem-
onstrated that general inhibition of the proteolytic activity of pro-
teasome results in a dramatic reduction of coxsackieviral
replication and virus-induced pathogenesis [5,6]. However, the
function of proteasome can to some degree be redundant. Treat-
ment with proteasome inhibitors has been shown to be able to in-
duce the development of adaptation conferring the cells with the
resistance to proteasome inhibition [16,17]. Alternative proteases
to the impaired proteasome have been identiﬁed [9]. TPPII is a
large serine peptidase which contributes to both protein turnover
and antigen presentation by further degrading proteasome-gener-
ated peptides [11]. Increasing evidence has suggested that TPPII,
under stress conditions, may compensate and substitute for the
function of the proteasome [10,16,17]. The present study explored
the potential role of TPPII in regulating CVB3 replication in the
presence and absence of proteasome inhibitor and demonstrated
an essential function of the TPPII in the maintenance of viral la-
tency after the loss of the proteasome activities.
The potential mechanisms by which the TPPII pathway assists
in CVB3 replication in the absence of functional proteasome is
likely related to its role in maintaining general protein turnover.
Many host intracellular proteins can function as barriers against
viral replication. For example, we have recently demonstrated
that tumor suppressor protein p53 is an anti-CVB3 host protein
and increased proteolysis of this protein is beneﬁcial to CVB3
replication [3]. We thus postulate that TPPII functions to main-
tain CVB3 replication by facilitating the degradation of anti-viral
host proteins.
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Fig. 4. Peptidase activities after the treatment with proteasome and TPPII inhibitors. HeLa cells were treated with different concentrations of vehicle (DMSO), MG132, and/or
TPPII inhibitor, as indicated in the ﬁgure for 5 h. The chymotrypsin-like activities of 20S proteasome (A, C) and the TPPII activities (B, D) in the cell lysates were measured
using the ﬂuorogenic substrates as described in Section 2. The results are expressed as the amount of AMC formed by the enzymatic cleavage of substrate (mean ± S.D., n = 3).
⁄P < 0.05; #P < 0.001compared to DMSO treated control group.
264 J. Zhang et al. / FEBS Letters 585 (2011) 261–265MG132 is a peptide aldehyde and inhibits the function of the
proteasome by acting as a proteasome substrate analog. In addition
to proteasome inhibition, MG132 can inhibit lysosomal and calpain
protease activities [25]. In this study, we also demonstrated a non-
speciﬁc effect of MG132 on the inhibition of the TPPII activities.
Thus, the striking inhibition effect of MG132 at the higher doses
on CVB3 replication shown in the previous studies [5,6] and in
the current study appears to be due to the blockage of both protea-
some and TPPII activities.
In conclusion, out data provide the ﬁrst evidence that TPPII can
partially substitute for compromised proteasome function to serve
as an alternative pathway to favor viral growth within the host
cells. These ﬁndings provide potentially useful information for no-
vel anti-viral drug design.
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